

1 **Associations of plasma omega-6 and omega-3 fatty acids with overall**
2 **and 19 site-specific cancers: a population-based cohort study in UK**
3 **Biobank**
4

5 Authors: Yuchen Zhang, MSPH¹; Yitang Sun, MPH²; Suhang Song, PhD³, Nikhil K. Khankari
6 PhD, MPH^{4,5}, J. Thomas Brenna, PhD^{6,7}; Ye Shen, PhD^{1*}; Kaixiong Ye, PhD^{2,8*}
7

8 **Author Affiliations:**

9 ¹ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,
10 Athens, Georgia, US

11 ² Department of Genetics, University of Georgia, Athens, Georgia, US

12 ³ Department of Health Policy and Management, College of Public Health, University of Georgia,
13 Athens, Georgia, US

14 ⁴ Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, US

15 ⁵ Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, US

16 ⁶ Division of Nutritional Sciences, Cornell University, Ithaca, NY, US

17 ⁷ Dell Pediatric Research Institute and the Depts of Pediatrics, of Nutrition, and of Chemistry,
18 University of Texas at Austin, Austin, TX, US

19 ⁸ Institute of Bioinformatics, University of Georgia, Athens, Georgia, US

20 * YS and KY jointly supervised this project.
21

22 **Corresponding Authors:**

23 Kaixiong Ye, PhD

24 Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East
25 Green Street, Athens, GA 30602

26 Phone: 706-542-5898 Email: kaixiong.ye@uga.edu
27

28 Ye Shen, PhD

29 Department of Epidemiology and Biostatistics, University of Georgia, 101 Buck Rd, Athens, GA
30 30602

31 Phone: 706-542-2754 Email: yeshen@uga.edu

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Abstract

Background

Previous epidemiological studies of the associations between polyunsaturated fatty acids (PUFAs) and cancer incidence have been inconsistent. We investigated the associations of plasma omega-3 and omega-6 PUFAs with the incidence of overall and 19 site-specific cancers in a large prospective cohort.

Methods

253,138 eligible UK Biobank participants were included in our study. With a mean follow-up of 12.9 years, 29,838 participants were diagnosed with cancer. The plasma levels of omega-3 and omega-6 PUFAs were expressed as percentages of total fatty acids (omega-3% and omega-6%).

Results

In our main models, both omega-6% and omega-3% were inversely associated with overall cancer incidence (HR per SD = 0.98, 95% CI = 0.96-0.99; HR per SD = 0.99, 95% CI = 0.97-1.00; respectively). Of the 19 site-specific cancers available, 14 were associated with omega-6% and five with omega-3%, all indicating inverse associations, with the exception that prostate cancer was positively associated with omega-3% (HR per SD = 1.03, 95% CI = 1.01 - 1.05).

Conclusions

Our population-based cohort study in UK Biobank indicates small inverse associations of plasma omega-6 and omega-3 PUFAs with the incidence of overall and most site-specific cancers, although there are notable exceptions, such as prostate cancer.

Keywords

Polyunsaturated fatty acids, Omega-6 fatty acids, Omega-3 fatty acids, Cancer incidence, Prospective cohort study

55 **Background**

56 Cancer is a leading cause of morbidity and mortality worldwide, with an estimated 18.1 million
57 cancer cases globally in 2020. Breast, lung, and colorectal cancer account for over 30% of the
58 total annual incidence [1]. Polyunsaturated fatty acids (PUFAs) have been postulated to influence
59 cancer incidence and survival [2-4]. Potential mechanisms of PUFAs in cancer etiology include
60 serving as precursors to lipid mediators regulating metabolic pathways and inflammatory
61 responses [5], and altering membrane composition that could affect cell signaling pathways [6].

62
63 Despite extensive interest and research, the links between PUFAs and cancer remain
64 inconclusive. An umbrella review of meta-analyses of observational studies of cancer incidence
65 concluded that there was no convincing evidence regarding the effects of omega-3 PUFAs on the
66 risk of any cancer, and that there was only weak evidence supporting inverse associations of
67 omega-3 intake with liver, breast, and brain cancers [3]. A meta-analysis of observational studies
68 of cancer survival found that the intake of fish or marine omega-3 PUFAs, but not total omega-3
69 PUFAs, was associated with lower mortality in cancer patients [7]. A meta-analysis of
70 randomized trials showed that increasing marine omega-3 PUFAs had little or no effects on
71 overall cancer diagnosis or cancer death, while the effects of increasing omega-6 PUFAs were
72 unclear because the evidence was of very low quality [2]. These systemic reviews showcase the
73 limitations of existing studies, which include large between-study heterogeneity, small study bias,
74 insufficient case numbers, and short follow-up time. Moreover, most studies relied on self-
75 reported fish oil supplementation or estimated dietary intake, which may suffer from recall errors,
76 outdated food databases, and measurement inaccuracy [8]. Circulating biomarkers provide more
77 objective measures of omega-3 and omega-6 PUFA status and are reflective of dietary intakes [9].
78 Indeed, a meta-analysis of prospective studies found that the blood level of omega-6 PUFAs, but
79 not their intake, was inversely associated with overall cancer risk [10]. Similarly, another meta-
80 analysis showed that the blood level of omega-3 PUFAs, but not their intake, was associated with
81 a lower colorectal cancer risk [11]. Addressing the limitations of current studies and examining
82 objective blood levels of PUFAs may offer clarity into the roles of omega-3 and omega-6 PUFAs
83 in cancer risk.

84

85 UK Biobank is a large population-based prospective cohort that has followed over 500,000
86 participants since 2006 [12]. It is a large homogeneous cohort with a long follow-up time,
87 offering an unprecedented opportunity to examine the effects of PUFAs on overall cancer and a
88 comprehensive range of site-specific cancers. A few early studies have revealed that fish oil
89 supplementation or dietary omega-3 PUFA intake was associated with lower incidence of colon
90 cancer, lung cancer, or liver cancer [13-15]. Recently, UK Biobank obtained metabolomic
91 measurements of baseline plasma samples for about 60% of the participants, a random subset of
92 the full cohort [16]. Leveraging this valuable dataset, we previously showed that circulating
93 levels of omega-3 and omega-6 PUFAs were both inversely associated with overall cancer
94 mortality [17]. In this study, we aim to examine the associations of circulating omega-3 and
95 omega-6 PUFAs, as well as their ratio (i.e., omega-6/omega-3), with the incidence of overall and
96 19 site-specific cancers in UK Biobank.

97

98 **Methods**

99 *Study population*

100 Between 2006 and 2010, UK Biobank recruited over half a million participants, aged 37-73, in
101 22 assessment centers across England, Wales and Scotland. During the baseline assessment visit,
102 a wide variety of sociodemographic, lifestyle, and health-related data were acquired through self-
103 administered touch-screen questionnaires, concise computer-assisted interviews, and physical
104 and functional measures. Blood, urine, and saliva samples were also collected. Of the 502,366
105 participants, those who had cancer diagnoses at baseline (n=37,737, excluding nonmelanoma
106 skin cancer with an ICD-10 code of C44), those who had withdrawn from UK Biobank
107 (n=1,227), and those with missing data on the plasma polyunsaturated fatty acids (n=210,264)
108 were excluded from our study. A total of 253,138 eligible participants were eventually included.

109 *Ascertainment of exposures*

110 The absolute concentrations of plasma polyunsaturated fatty acids (PUFAs) were assessed using
111 nuclear magnetic resonance (NMR) in plasma samples obtained at the baseline visit from 2007 to
112 2010, and the corresponding percentages of total fatty acids were calculated [12, 16]. The
113 omega-3 fatty acids to total fatty acids percentage (omega-3%) and the omega-6 fatty acids to

114 total fatty acids percentage (omega-6%) were the primary exposures of interest in this study. In
115 addition, we conducted analyses on the ratio of plasma omega-6/omega-3 PUFAs,
116 docosahexaenoic acid to total fatty acids percentage (DHA%), and linoleic acid to total fatty
117 acids percentage (LA%). No other individual PUFAs, except DHA and LA, were measured by
118 the NMR metabolomic platform.

119 *Ascertainment of outcomes*

120 The primary outcomes were the first incidence of overall and 19 site-specific cancers based on
121 diagnostic records in cancer registers ascertained from National Health Service (NHS) central
122 registers [12]. At the time of our analysis (15 August 2023), we had access to the most current
123 health outcomes dataset (Version: July 2023), which contained cancer incidence records up to 19
124 December 2022. Consequently, follow-up time was calculated from the recruitment date until the
125 aforementioned date, any cancer diagnosis or death, whichever came first. The incidence of
126 cancer was coded according to the World Health Organization's International Statistical
127 Classification of Diseases (ICD)-9 or ICD-10 codes. Participants who had cancer at baseline
128 (excluding nonmelanoma skin cancer) were excluded. ICD-9 codes were only used for pre-
129 existing cancer and thus excluded. New cancer incidence was defined based on ICD-10 codes
130 for overall cancer (C00-C97, excluding nonmelanoma skin cancer, C44) and the following 19
131 site-specific cancers: head and neck (C00-C14), esophagus (C15), stomach (C16), colon (C18),
132 rectum (C19-C20), hepatobiliary tract (C22-C24), pancreas (C25), lung (C33-C34), malignant
133 melanoma (C43), connective soft tissue (C49), breast (C50), uterus (C54-C55), ovary (C56),
134 prostate (C61), kidney (C64-C65), bladder (C66-C67), brain (C70-C72), thyroid (C73), and
135 lymphoid and hematopoietic tissues (C81-C96).

136 *Covariates*

137 The initial questionnaire covered a comprehensive range of potential confounding factors:
138 demographic characteristics (e.g., age, gender, ethnicity); socioeconomic status, as measured by
139 the Townsend Deprivation Index (TDI); lifestyle behaviors (e.g., alcohol consumption, smoking
140 status, body mass index (BMI), and physical activity); and history or family history of diseases
141 (e.g., diabetes, gastroesophageal reflux disease and family history of cancer). Body mass index
142 (BMI) was calculated from weight and height expressed in kg/m^2 . Waist circumference and hip
143 circumference were recorded at a central registry, and we calculated the corresponding waist-hip

144 ratio (waist circumference divided by hip circumference). The TDI, employed as a measure of
145 socioeconomic deprivation, was directly obtained from the UK Biobank database, with a higher
146 score indicating a higher level of socioeconomic deprivation.

147 *Statistical analyses*

148 We began by summarizing and comparing participant characteristics based on the quintiles of the
149 plasma omega-6% and omega-3% at baseline using descriptive statistics. To assess the
150 differences in demographic features across these quintiles, we employed Pearson's Chi-squared
151 test for categorical variables and the ANOVA test for continuous variables.

152
153 To explore the associations with cancer incidence for plasma omega-6%, omega-3%, and their
154 ratio, we utilized multivariable Cox proportional hazards regression models to estimate hazard
155 ratios (HRs) along with their corresponding 95% confidence intervals (CIs). We developed three
156 distinct models, namely, the simply adjusted model, the main model, and the additionally
157 adjusted model. Within the simply adjusted model, age and sex were designed as stratification
158 variables owing to their violation of the assumptions inherent to the proportional hazards model.
159 The main model was additionally adjusted for ethnicity (classified into White, Black, Asian,
160 Others), TDI (continuous), assessment center (categorical), BMI (kg/m²; continuous), smoking
161 status (categorized as never, previous, current), alcohol intake status (categorized as never,
162 previous, current), and physical activity (classified as low, moderate, high). In addition to
163 investigating the overall cancer, we also performed separate analyses for each site-specific cancer.
164 The analysis of prostate cancer was restricted to the male sample, whereas the investigation of
165 breast cancer, ovarian cancer, and uterine cancer was limited to the female sample. Furthermore,
166 to adjust for additional possible confounding variables, we incorporated additional covariates
167 into the analysis for certain cancer types (i.e., additionally adjusted models), guided by previous
168 literature and biological plausibility [15]. More details can be found in Table S1.

169
170 Our analysis treated the exposures of interest both in continuous (standardized to a mean of 0 and
171 standard deviation of 1) and categorical (in quintiles) terms. When conducting trend tests, we
172 used the median value of each quintile as a continuous variable within the models. Given 19
173 distinct cancer subtypes, we adopted the False Discovery Rate (FDR) approach to address the
174 issue of increasing false positives arising from multiple testing and reported the adjusted p-

175 values for simply adjusted models and main models. We did not perform multiple testing
176 correction for the additionally adjusted models because they were for the purpose of sensitivity
177 analysis and were only performed for 10 site-specific cancers with site-specific covariates. We
178 also evaluated potential nonlinear dose-response using a semi-parametric approach through the
179 utilization of restricted cubic splines [18] (4 knots were used in regression splines). We
180 considered there was evidence supporting the presence of an association between a PUFA
181 exposure and a cancer outcome if the continuous exposure analysis or the trend across quintiles
182 analysis was statistically significant in the main models or in the additionally adjusted models, if
183 applicable. In addition to the two above-described analyses, we assessed if there were any
184 differences among the HRs across the five quintiles by applying likelihood ratio tests.

185
186 In secondary analyses aiming at investigating potential variations in associations within distinct
187 population subgroups, we replicated the aforementioned analyses for overall cancer while
188 stratifying the data by the following factors: age (< vs. \geq the median age of 58 years), sex (male
189 vs. female), TDI (< vs. \geq the population median of -2), BMI (< vs. \geq 25), current smoking status
190 (yes vs. no), current alcohol consumption status (yes vs. no) and level of physical activity (low
191 and moderate vs. high). The exposures of interest (omega-6%, omega-3%, and their ratio) were
192 categorized in quintiles. For each stratification variable, we conducted a likelihood ratio test to
193 obtain the associated p-value for interaction. In the case of continuous stratification variables (i.e.,
194 age, TDI, and BMI), we calculated interaction p-values based on a one-unit alteration of the
195 respective stratification variables.

196
197 Furthermore, we carried out a series of sensitivity analyses. First, to assess whether the
198 association of plasma omega-6% with overall cancer risk would be altered by omega-3% or vice
199 versa, we replicated the main analysis for overall cancer while involving both omega-6% and
200 omega-3% as variables in the model. The correlation between omega-3% and omega-6% was
201 assessed by the Pearson correlation. Second, to explore the effects of individual fatty acids, DHA
202 and LA, on cancer incidence, we repeated the main analysis on DHA% and LA%. Third, to
203 investigate the potential impact of reverse causation on the observed associations, individuals
204 who experienced outcomes within the first year or the first three years of the follow-up period
205 were excluded from the analysis. Last, to evaluate the representativeness of the study participants,

206 we conducted a comparative analysis of baseline characteristics between those individuals with
207 exposure information and those without it. All p-values were assessed using a two-sided
208 approach. Statistical significance was defined as a p-value less than 0.05 or a 95% confidence
209 interval that did not include the value 1.0 for the corresponding HRs. We conducted all analyses
210 using R (version: 4.0.3).

211

212 **Results**

213 *Baseline characteristics*

214 Within our analytical cohort of 253,138 participants, spanning an average follow-up period of
215 12.9 years, a total of 29,838 individuals were diagnosed with cancer during follow-up. The
216 baseline characteristics of all participants distributed across quintiles of plasma omega-6% and
217 omega-3% were summarized in Table 1 and Table S2, respectively. On average, study
218 participants were approximately 56 years old, with 90% of them identifying as White. Those in
219 the higher quintiles of plasma omega-6% tended to be younger, female, with lower BMI and
220 more physically active, and were less likely to smoke or drink alcohol.

221 *Associations of plasma omega-6, omega-3, and their ratio with cancer risk*

222 The findings for the associations of plasma omega-6% and omega-3% with the incidence of
223 overall and site-specific cancer are shown in Figure 1, with more detailed information in Tables 2
224 and 3. In the main models with continuous omega-6% and omega-3%, each standard deviation
225 (SD) increase in the percentage was associated with a 2% (HR per SD = 0.98, 95% CI = 0.96-
226 0.99, $p < 0.01$) and 1% (HR per SD = 0.99, 95% CI = 0.97 - 1.00, $p = 0.03$) decline in risk of
227 overall cancer for omega-6% and omega-3%, respectively. Additionally, categorizing omega-6%
228 and omega-3% into quintiles revealed that higher concentrations were linked to a decreased
229 overall cancer risk, with a significant trend observed for both omega-6% and omega-3% ($p_{\text{trend}} <$
230 0.05).

231

232 We performed similar analyses for 19 site-specific cancers. In the main models with continuous
233 exposure, omega-6% was inversely associated with the risk of 13 site-specific cancers (corrected
234 $p < 0.05$, Figure 1). If considering the trend across the quintiles in the main models, all but two
235 site-specific cancers had inverse associations with omega-6%. The two exceptions were prostate

236 cancer and malignant neoplasms of lymphoid and hematopoietic tissues (corrected $p_{\text{trend}} < 0.05$,
237 Table 2). As for omega-3%, only five site-specific cancers had significant associations in the
238 main analysis with continuous exposure (Figure 1), and the trend analysis across quintiles did not
239 reveal additional significant associations (Table 3). Cancers at four sites, including stomach,
240 colon, hepatobiliary tract, and lung, were inversely associated with both omega-6% and omega-
241 3%. Only one site-specific cancer, prostate cancer, was associated with omega-3% (HR per SD =
242 1.03, 95% CI = 1.01 - 1.05, corrected $p = 0.049$) but not omega-6% (HR per SD = 1.01, 95% CI
243 = 0.98 - 1.03, corrected $p = 0.56$). In the sensitivity analysis of 10 site-specific cancers by
244 additionally adjusting for site-specific covariates, most of the above-mentioned significant
245 associations remained, except the associations of omega-6% with cancers at breast, uterus, and
246 ovary (Figure 2). In summary, we counted associations that were statistically significant in the
247 main models with either continuous exposure analysis or trend analysis, and that remain
248 significant after adjusting for additional site-specific covariates when appropriate. There were 14
249 site-specific cancers associated with omega-6% and five with omega-3%, with an overlap of four
250 between these two groups. Only four site-specific cancers (i.e., ovary, breast, uterus, and
251 lymphoid and hematopoietic tissues) were not associated with either omega-3% or omega-6%.

252
253 We also conducted analysis of the omega-6/omega-3 ratio (Table S3, Figure S1). A higher
254 omega-6/omega-3 ratio was associated with a higher overall cancer risk ($p_{\text{trend}} = 0.038$). A total
255 of three site-specific cancers showed evidence of positive associations with the ratio. Every SD
256 increment in the ratio was associated with a 2% increase in the risk of rectum cancer, and the
257 association remained unchanged after additionally controlling for site-specific covariates (per SD
258 HR = 1.02, 95% CI = 1.01 - 1.03, $p = 0.003$). When examining trends across quintiles, lung
259 cancer was significant in the main model (corrected $p_{\text{trend}} = 0.011$) and remained significant after
260 adjusting for additional covariates ($p_{\text{trend}} < 0.001$). Colon cancer was significant in the
261 additionally adjusted model ($p_{\text{trend}} = 0.015$).

262
263 In addition to the trend analysis across quintiles, we assessed if there were any differences across
264 the association effect sizes of quintiles by applying likelihood ratio tests. Most of the PUFAs-
265 cancer relationships with significant trends were also statistically significant in the overall
266 likelihood ratio tests. On the other hand, there were two pairs of relationships whose trend

267 analyses were not significant, but their overall tests were. The most notable pair was omega-6%
268 and prostate cancer (additionally adjusted model, $p_{\text{trend}} = 0.72$, $p_{\text{overall}} = 0.005$). The association
269 estimates across the quintiles support the presence of a nonlinear relationship: Quintile 2 (HR =
270 1.10, 95% CI = 1.02 - 1.18), Quintile 3 (HR = 1.09, 95% CI = 1.01 - 1.17), Quintile 4 (HR =
271 1.09, 95% = 1.00 - 1.17), and Quintile 5 (HR = 0.98, 95% CI = 0.90-1.06). The other pair was
272 omega-6% and uterus cancer (additionally adjusted model, $p_{\text{trend}} = 0.97$, $p_{\text{overall}} = 0.022$), and
273 there was an inverse association in the Quintile 5 (HR = 0.81, 95% CI = 0.66-0.99).

274 *Stratified analyses for plasma omega-6 and omega-3 fatty acids*

275 Stratified analyses were conducted to assess potential effect modifications by age, sex, TDI, BMI,
276 smoking status, alcohol consumption status, and physical activity, as shown in Table 4. The
277 observed inverse associations of plasma omega-6% with overall cancer risk appeared to be
278 notably more pronounced in the younger age group (p for interaction < 0.001) and in females (p
279 for interaction = 0.006), with no apparent modification by the remaining potential stratification
280 variables. Moreover, the estimated inverse associations of plasma omega-3% with overall cancer
281 risk demonstrated a tendency to be stronger in the older group (p for interaction < 0.001), in
282 males (p for interaction = 0.002), and in current smokers (p for interaction = 0.017).

283 *Restricted cubic spline analysis*

284 In the restricted cubic spline analysis, it is noteworthy that significant inverse associations were
285 observed for omega-6% and omega-3% with the overall cancer incidence ($p < 0.05$ for both
286 variables, as shown in Figure S2). Moreover, potential nonlinearity was identified for the
287 relationship between omega-3% and overall cancer incidence ($p < 0.05$). This finding suggests
288 that the protective effect of omega-3 PUFAs may exhibit enhanced efficacy at the lower
289 concentration level. Due to the possible presence of a nonlinear association between omega-6%
290 and prostate cancer, we further performed cubic spline analysis for prostate cancer. We found
291 evidence of nonlinearity between omega-6% and prostate cancer, with the intermediate level of
292 omega-6% associated with the highest risk ($p = 0.02$, Figure S3).

293 *Sensitivity analyses*

294 In order to evaluate whether the associations between plasma omega-6% and overall cancer risk
295 might undergo modification by omega-3%, or vice versa, both omega-6% and omega-3% were

296 simultaneously integrated into the same models (as detailed in Table S4 and Table S5). The
297 correlation between plasma omega-6% and omega-3% was relatively low, with $r = -0.12$ ($p <$
298 0.01). After their inclusion in the same models, the associations of both plasma omega-6% and
299 omega-3% with overall cancer risk remained statistically significant. The results for DHA% and
300 LA% were consistent with those for omega-3% and omega-6%, respectively (as detailed in Table
301 S6 and Table S7). Additionally, when we excluded participants who experienced cancer or death
302 within the first year or the first three years of follow-up, the outcomes remained unchanged (as
303 detailed in Table S8 and Table S9). It is worth noting that the baseline characteristics were
304 comparable between participants with and without exposure information, as evidenced by Table
305 S10.

306

307 Discussion

308 Our population-based prospective cohort study in UK Biobank revealed that higher plasma
309 omega-6% and omega-3% were both associated with a lower incidence of overall cancer. The
310 overall association effect sizes in the main model were 2% and 1% reductions per SD of omega-
311 6% and omega-3%, respectively. The association of omega-6% with cancer risk was independent
312 of most risk factors examined, including TDI, BMI, smoking status, alcohol status, and physical
313 activity. The observed inverse associations of plasma omega-6% appeared to be notably more
314 pronounced in the younger age group and in women. On the other hand, the inverse associations
315 of plasma omega-3% with overall cancer incidence were stronger in the older age group, in men,
316 and in current smokers. The inverse associations of omega-6% and omega-3% with overall
317 cancer incidence were robust to a list of sensitivity analyses. In terms of the incidence of 19 site-
318 specific cancers, 14 were associated with omega-6% and five with omega-3%, all exhibiting
319 inverse associations (3% - 7% reduced risk per SD of omega-6%; 5% - 8% reduced risk per SD
320 of omega-3%), with the exception that prostate cancer was positively associated with omega-3%
321 (3% increased risk). Only four site-specific cancers (i.e., ovary, breast, uterus, and lymphoid and
322 hematopoietic tissues) were not associated with either omega-3% or omega-6%.

323

324 Despite a large number of studies, the links between PUFAs, especially omega-6 PUFAs, and the
325 incidence of overall cancer remain ill-defined. Most existing studies examined dietary PUFAs or

326 supplements, instead of circulating biomarkers. A 2019 prospective cohort study found no
327 significant associations of omega-3 or omega-6 PUFA intakes with the overall cancer incidence
328 [19]. A 2020 meta-analysis of randomized trials showed that increasing dietary long-chain
329 omega-3 PUFAs had little or no effects on overall cancer diagnosis or cancer death, while the
330 effects of increasing dietary omega-6 PUFAs were unclear because the evidence was of very low
331 quality [2]. A 2022 meta-analysis of observational studies revealed that fish intake and marine
332 omega-3 PUFA intake were associated with lower mortality in patients with overall cancer [7].
333 Of note, a 2020 meta-analysis of prospective studies showed that the blood level of omega-6
334 PUFAs (highest vs. lowest category RR = 0.92, 95% CI = 0.86 - 0.98), but not their intake, was
335 inversely associated with overall cancer risk [10]. They also found that the protective association
336 was stronger in women than in men, consistent with our findings. In the context of UK Biobank,
337 a 2021 prospective study demonstrated that regular fish oil supplementation was associated with
338 a lower incidence of overall cancer, but only in participants who consumed fatty fish less than
339 two times per week (HR = 0.96, 95% CI = 0.94 - 0.99), not in those who consumed more than
340 twice per week (HR = 1.01, 95% CI = 0.95 - 1.07). Their subgroup analysis further unraveled
341 that men were more likely to gain benefits from fish oil supplementation than women [15].
342 Consistently, our study found that the plasma level of omega-3 PUFAs was inversely associated
343 with overall cancer incidence and that the association was only significant in men. Moreover, a
344 2023 study of circulating PUFAs and cancer mortality by our group revealed that both plasma
345 omega-3 and omega-6 PUFAs were inversely associated with cancer mortality (highest vs.
346 lowest quintile HR = 0.75, 95% = 0.65 - 0.87; HR = 0.80, 95% CI = 0.68 - 0.92; respectively)
347 [17]. Overall, our findings provide support for possible small net protective roles of omega-3 and
348 omega-6 PUFAs in the development of new cancer incidence. Our study also suggests that the
349 usage of circulating blood biomarkers captures different aspects of dietary intake, reduces
350 measurement errors, and thus enhances statistical power. The differential effects of omega-6%
351 and omega-3% in age and sex subgroups warrant future investigation.

352
353 In our study, we observed site-specific associations of omega-3 PUFAs with cancer incidence. A
354 higher plasma level of omega-3 PUFAs was associated with a significant reduction in the
355 incidence of digestive system cancers (including colon, stomach, and hepatobiliary tract) and
356 lung cancer. However, it appeared to be linked to an increased risk of prostate cancer. The

357 observed protective associations between plasma omega-3 PUFAs and the incidence of digestive
358 system cancers and lung cancer are consistent with recent studies of fish oil supplementation and
359 dietary intake in UK Biobank [13-15]. Regular fish oil supplementation was associated with
360 lower incidence of colon cancer (HR = 0.88, 95% CI = 0.8-0.98), hepatobiliary cancer (HR =
361 0.72, 95% CI = 0.58-0.91), and lung cancer (HR = 0.87, 95% CI = 0.78-0.96) [15]. Another
362 independent analysis of UK Biobank data revealed a 44% lower risk of liver cancer incidence
363 among fish oil users [14]. Dietary intake of omega-3 PUFAs was associated with an 18%
364 decreased risk in lung cancer incidence (HR=0.82, 95% CI= 0.73-0.93; per 1g/d) [13]. Notably,
365 some studies and meta-analyses did not find significant associations of dietary omega-3 PUFAs
366 and fish oil supplementation with colorectal cancer [3, 20, 21]. However, a recent meta-analysis
367 showed that while the dietary intake of omega-3 PUFAs was not associated with the colorectal
368 cancer risk (relative risk, RR = 0.97, 95% CI = 0.90 - 1.04 for the highest versus lowest
369 category), the blood level of omega-3 PUFAs was associated with a lower risk (RR = 0.79, 95%
370 CI = 0.64 - 0.98) [11]. Regarding prostate cancer, most studies did not find significant
371 associations with dietary intake or blood level of omega-3 PUFAs [3, 15, 22-24]. However, the
372 few statistically significant findings suggest that dietary intake of alpha-linolenic acid (ALA)
373 was associated with a lower prostate cancer risk, while both dietary intake and blood level of
374 DHA were associated with a higher risk [3, 23, 25]. Our study found that plasma omega-3% and
375 DHA% were both positively associated with the risk of prostate cancer. Further studies are
376 warranted to explore the roles of individual omega-3 PUFAs in the etiology of prostate cancer.

377
378 In our investigation of omega-6 PUFAs, we observed inverse associations of plasma omega-6
379 PUFAs with 14 site-specific cancers at head and neck, esophagus, stomach, colon, rectum,
380 hepatobiliary tract, pancreas, lung, malignant melanoma, connective soft tissue, kidney, bladder,
381 brain, and thyroid. Moreover, an increased omega-6/omega-3 PUFAs ratio was associated with
382 elevated risks of rectum, colon, and lung cancer. Notably, the evidence on the associations
383 between omega-6 PUFAs, the omega-6/omega-3 ratio, and site-specific cancers was limited and
384 exhibited varying results. Two prospective cohort studies did not establish significant links
385 between dietary omega-6 PUFAs and colorectal cancer [20, 21]. However, in agreement with our
386 findings, another prospective cohort study observed that omega-6 PUFA intake was inversely
387 associated with the risk of digestive cancer (including esophagus, liver, stomach, pancreas, and

388 colorectal) (highest vs. lowest quintile HR = 0.56, 95% CI = 0.32 - 0.97) or colorectal cancer
389 alone (HR = 0.43, 95% CI = 0.22 - 0.83)(19). Also consistent with our results, a prospective
390 cohort study based on UK Biobank indicated a modest protective effect of dietary omega-6
391 PUFAs against lung cancer (HR = 0.98, 95% CI = 0.96-0.99; per 1g/d) [13]. A systematic review
392 and meta-analysis of eight previous studies also found no apparent association between dietary
393 omega-6 PUFAs and prostate cancer [23], in line with our findings from trend analysis.
394 However, we did find evidence for the possible presence of a nonlinear relationship, with
395 intermediate levels of omega-6% associated with the highest risk of prostate cancer. There were
396 three site-specific cancers at breast, uterus, and ovary that were inversely associated with plasma
397 omega-6% in our main models, but these associations disappeared after controlling for site-
398 specific covariates, such as age of menarche, hormone replacement therapy use, oral
399 contraceptive use, number of live births, menopausal status, and hysterectomy status. A previous
400 meta-analysis of prospective studies did observe an inverse association of the blood omega-6
401 level with breast cancer (highest vs. lowest category RR = 0.87; 95% CI: 0.77–0.98) [10]. Our
402 study indicated that the consideration of site-specific covariates is critical in interpreting
403 associations.

404
405 This study has several strengths. The major strength was the prospective population-based study
406 design in UK Biobank, which provides a large sample size, long duration of follow-up, and
407 detailed information on potential confounding variables. We used the objective measurements of
408 PUFA biomarkers in plasma instead of the estimated dietary intakes from self-reported
409 questionnaires, which increases the accuracy of exposure assessment. Moreover, the cancer
410 incidence data were acquired through cancer registries to reduce selection bias. This approach
411 ensures a more representative sample, as these registries comprehensively cover a wide range of
412 demographics and cancer types, and adhere to standardized data collection protocols, thereby
413 enhancing the reliability and generalizability of our findings [26]. Furthermore, we adopted the
414 FDR approach when investigating site-specific cancers, to address the issue of increasing false
415 positives from multiple comparisons. In several sensitivity analyses, most of the associations
416 remain materially unchanged, indicating the robustness of our results.

417

418 Some potential limitations warrant consideration in the interpretation of our findings. First,
419 despite previous indications of the representativeness of UK Biobank in sociodemographic and
420 health-related characteristics of the UK population, the potential for selective bias persists [27,
421 28]. Notably, the participant sample skewed heavily toward European ancestry and White
422 ethnicity, necessitating caution in generalizing results across diverse ancestral backgrounds and
423 ethnicities. Secondly, while we adjusted for multiple potential confounding variables in our
424 model, the inherent limitations of observational studies preclude the complete elimination of
425 inaccuracies in measurements, unmeasured variables, and interdependencies among factors.
426 Thirdly, the number of events was small for some specific cancer sites, which may lead to the
427 limited statistical power of our study. Fourthly, our study focused on total omega-3 and omega-6
428 PUFAs. There are only two individual PUFAs measured in the UK Biobank cohort, LA and DHA.
429 We showed that the associations of LA% mirrored those of omega-6%, while DHA% mirrored
430 omega-3%. Future studies into other individual PUFAs are needed. Lastly, despite the relative
431 homogeneity of the sample, individual genetics have not been taken into account. Future studies
432 are warranted to examine if specific genetic variants or composite genetic scores modify the
433 associations of circulating PUFAs with overall or site-specific cancers.

434

435 **Conclusion**

436 In our UK Biobank prospective cohort study, elevated levels of plasma omega-6 and omega-3
437 PUFAs were linked to reduced overall cancer risk, while a higher omega-6/omega-3 ratio was
438 associated with increased risk. The associations of omega-6 PUFAs were stronger in the younger
439 age group and in women, while the associations of omega-3 PUFAs were more prominent in the
440 older group, in men, and in current smokers. Our findings extended to the inverse associations of
441 plasma omega-6 and omega-3 PUFAs with 14 site-specific cancers. One notable exception to this
442 trend of protective association was between omega-3 PUFAs and prostate cancer. Our study laid
443 a solid foundation for future mechanistic studies into the roles of PUFAs in the etiology of
444 various cancers. It also provided insights into the development of cancer prevention strategies by
445 managing circulating PUFAs.

446

447 **Figure Legends**

448 **Figure 1.** Risk estimates of the incidence of overall cancer and 19 cancer sites for 1-SD increase
449 of plasma omega-6% and omega-3%, for simply adjusted and main models. The results from
450 simply adjusted models revealed the associations stratified by age and sex in the general cohort.
451 The main models were adjusted for general covariates, including ethnicity (classified into White,
452 Black, Asian, Others), Townsend deprivation index (continuous), assessment Center, BMI
453 (kg/m²; continuous), smoking status (categorized as never, previous, current), alcohol intake
454 status (categorized as never, previous, current), and physical activity (classified as low, moderate,
455 high). P values were corrected for the multiple testing of 19 site-specific cancers.

456
457 **Figure 2.** Risk estimates of the incidence of overall cancer and specific cancer sites for 1-SD
458 increase of plasma omega-6% and omega-3%, for additionally adjusted models. For esophagus
459 cancer, additionally adjusted for gastroesophageal reflux disease at baseline and waist-hip ratio.
460 For colon cancer and rectum cancer, additionally adjusted for diabetes at baseline, aspirin use,
461 processed meat intake, waist-hip ratio, and family history. For pancreas cancer, additionally
462 adjusted for diabetes at baseline. For lung cancer, additionally adjusted for family history. For
463 malignant melanoma cancer, additionally adjusted for skin color, ease of skin tanning, use of
464 sun/UV protection, childhood sunburn occasions, frequency of solarium/sunlamp use. For breast
465 cancer, restricted to female, and additionally adjusted for age when menarche started, hormone
466 replacement therapy use, oral contraceptive use, number of live births, menopausal status,
467 hysterectomy status, and family history. For uterus and ovary cancer, restricted to female, and
468 additionally adjusted for age when menarche started, hormone replacement therapy use, oral
469 contraceptive use, number of live births, menopausal status, hysterectomy status. For prostate
470 cancer, restricted to male, and additionally adjusted for family history.

471

472 **Additional Information**

473 *Acknowledgements*

474 This research has been conducted using the UK Biobank Resource under Application Number
475 48818. This work uses data provided by patients and collected by the NHS as part of their care
476 and support. These data are copyrighted, 2022, NHS England. Reused with the permission of the
477 NHS England and UK Biobank. All rights reserved. This research used data assets made

478 available by National Safe Haven as part of the Data and Connectivity National Core Study, led
479 by Health Data Research UK in partnership with the Office for National Statistics and funded by
480 UK Research and Innovation (grant ref MC_PC_20058). We would like to express our heartfelt
481 gratitude to the UK Biobank participants and administrative staff.

482 *Authors' contributions*

483 YZ performed data analysis, prepared visualizations, and wrote the original draft of the
484 manuscript. YS and SS contributed to the data analysis. NKK and JTB contributed to the
485 interpretations of results. YS (yeshen@uga.edu) and KY (kaixiong.ye@uga.edu) contributed
486 equally to this project and should be considered co-corresponding authors. They jointly designed
487 and supervised the project. All authors critically edited the manuscript for important intellectual
488 content. The corresponding author (KY) attests that all listed authors meet the authorship criteria
489 and that no others meeting the criteria were omitted.

490 *Ethics approval and consent to participate*

491 The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/
492 NW/0382). Written informed consent was obtained from participants.

493 *Consent for publication*

494 Not applicable.

495 *Data availability*

496 The datasets analyzed during the current study are available from the UK Biobank through an
497 application process (www.ukbiobank.ac.uk/).

498 *Competing interests*

499 The authors declare no competing interests.

500 *Funding information*

501 Research reported in this publication was supported by the National Institute of General Medical
502 Sciences of the National Institute of Health under the award number R35GM143060 (KY). The
503 content is solely the responsibility of the authors and does not necessarily represent the official
504 views of the National Institutes of Health.

505

507 **References**

- 508 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of
509 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic
510 analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396(10258):1204-22.
- 511 2. Hanson S, Thorpe G, Winstanley L, Abdelhamid AS, Hooper L, Abdelhamid A, et al.
512 Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review
513 and meta-analysis of randomised trials. *British Journal of Cancer*. 2020;122(8):1260-70.
- 514 3. Lee KH, Seong HJ, Kim G, Jeong GH, Kim JY, Park H, et al. Consumption of Fish and
515 ω -3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational
516 Studies. *Advances in Nutrition*. 2020;11(5):1134-49.
- 517 4. Shahidi F, Ambigaipalan P. Omega-3 Polyunsaturated Fatty Acids and Their Health
518 Benefits. *Annu Rev Food Sci Technol*. 2018;9:345-81.
- 519 5. Gleissman H, Johnsen JI, Kogner P. Omega-3 fatty acids in cancer, the protectors of good
520 and the killers of evil? *Exp Cell Res*. 2010;316(8):1365-73.
- 521 6. Diggie CP. In vitro studies on the relationship between polyunsaturated fatty acids and
522 cancer: tumour or tissue specific effects? *Prog Lipid Res*. 2002;41(3):240-53.
- 523 7. Wang YP, Liu K-J, Long T, Long J, Li Y, Li J, Cheng L. Dietary fish and omega-3
524 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis.
525 *Critical Reviews in Food Science and Nutrition*. 2022;63:6235 - 51.
- 526 8. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies.
527 *Epidemiol Health*. 2014;36:e2014009.
- 528 9. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood
529 in humans and its use as a biomarker of dietary intake. *Prog Lipid Res*. 2008;47(5):348-80.
- 530 10. Kim Y, Kim J. N-6 Polyunsaturated Fatty Acids and Risk of Cancer: Accumulating
531 Evidence from Prospective Studies. *Nutrients*. 2020;12(9).
- 532 11. Kim Y, Kim J. Intake or Blood Levels of n-3 Polyunsaturated Fatty Acids and Risk of
533 Colorectal Cancer: A Systematic Review and Meta-analysis of Prospective Studies. *Cancer*
534 *Epidemiol Biomarkers Prev*. 2020;29(2):288-99.
- 535 12. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
536 access resource for identifying the causes of a wide range of complex diseases of middle and old
537 age. *PLoS Med*. 2015;12(3):e1001779.

- 538 13. Chen T, Song L, Zhong X, Zhu Q, Huo J, Chen J, et al. Dietary polyunsaturated fatty
539 acids intake, air pollution, and the risk of lung cancer: A prospective study in UK biobank.
540 *Science of The Total Environment*. 2023;882:163552.
- 541 14. Jiang W, Li F-R, Yang H-H, Chen G-C, Hua Y-F. Relationship between fish oil use and
542 incidence of primary liver cancer: findings from a population-based prospective cohort study.
543 *Frontiers in Nutrition*. 2021;8:771984.
- 544 15. Liu Z, Luo Y, Ren J, Yang L, Li J, Wei Z, et al. Association between fish oil
545 supplementation and cancer risk according to fatty fish consumption: A large prospective
546 population-based cohort study using UK Biobank. *International Journal of Cancer*.
547 2022;150(4):562-71.
- 548 16. Julkunen H, Cichońska A, Tiainen M, Koskela H, Nybo K, Mäkelä V, et al. Atlas of
549 plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank.
550 *Nature Communications*. 2023;14(1):604.
- 551 17. Zhang Y, Sun Y, Yu Q, Song S, Brenna JT, Shen Y, Ye K. Higher ratio of plasma omega-
552 6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular
553 mortality: a population-based cohort study in UK Biobank. *eLife Sciences Publications, Ltd*;
554 2023.
- 555 18. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*.
556 1989;8(5):551-61.
- 557 19. Sellem L, Srour B, Guéraud F, Pierre FHF, Kesse-Guyot E, Fiolet T, et al. Saturated,
558 mono- and polyunsaturated fatty acid intake and cancer risk: results from the French prospective
559 cohort NutriNet-Santé. *European Journal of Nutrition*. 2019;58:1515-27.
- 560 20. Nguyen SM, Li H-L, Yu D, Cai H, Gao J, Gao Y-T, et al. Dietary fatty acids and
561 colorectal cancer risk in men: A report from the Shanghai Men's Health Study and a
562 meta-analysis. *International Journal of Cancer*. 2020;148:77 - 89.
- 563 21. Song M, Chan AT, Fuchs CS, Ogino S, Hu FB, Mozaffarian D, et al. Dietary intake of
564 fish, ω -3 and ω -6 fatty acids and risk of colorectal cancer: A prospective study in U.S. men and
565 women. *International Journal of Cancer*. 2014;135(10):2413-23.
- 566 22. Aucoin M, Cooley K, Knee C, Fritz H, Balneaves LG, Breau R, et al. Fish-Derived
567 Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review. *Integr Cancer Ther*.
568 2017;16(1):32-62.

- 569 23. Chua ME, Sio MCD, Sorongon MC, Dy JS. Relationship of Dietary Intake of Omega-3
570 and Omega-6 Fatty Acids with Risk of Prostate Cancer Development: A Meta-Analysis of
571 Prospective Studies and Review of Literature. *Prostate Cancer*. 2012;2012:826254.
- 572 24. Farrell SW, DeFina LF, Tintle NL, Leonard D, Cooper KH, Barlow CE, et al. Association
573 of the Omega-3 Index with Incident Prostate Cancer with Updated Meta-Analysis: The Cooper
574 Center Longitudinal Study. *Nutrients*. 2021;13(2):384.
- 575 25. Fu Y-Q, Zheng J-S, Yang B, Li D. Effect of Individual Omega-3 Fatty Acids on the Risk
576 of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Prospective
577 Cohort Studies. *Journal of Epidemiology*. 2015;25(4):261-74.
- 578 26. Allen NE, Lacey B, Lawlor DA, Pell JP, Gallacher J, Smeeth L, et al. Prospective study
579 design and data analysis in UK Biobank. *Sci Transl Med*. 2024;16(729):eadf4428.
- 580 27. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor
581 associations in UK Biobank against representative, general population based studies with
582 conventional response rates: prospective cohort study and individual participant meta-analysis.
583 *Bmj*. 2020;368:m131.
- 584 28. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
585 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those
586 of the General Population. *Am J Epidemiol*. 2017;186(9):1026-34.
- 587

Plasma omega-6 PUFAs

Plasma omega-3 PUFAs

Cancer type	Events		HR (95% CI)	P value		HR (95% CI)	P value
Overall							
Simply adjusted model	29,838		0.94 (0.93-0.95)	<0.001		0.96 (0.95-0.97)	<0.001
Main model	23,628		0.98 (0.96-0.99)	0.001		0.99 (0.97-1.00)	0.033
Head and neck							
Simply adjusted model	6,249		0.94 (0.91-0.96)	<0.001		0.95 (0.93-0.98)	<0.001
Main model	4,933		0.97 (0.94-1.00)	0.061		0.97 (0.95-1.00)	0.111
Esophagus							
Simply adjusted model	3,217		0.89 (0.86-0.92)	<0.001		0.92 (0.88-0.95)	<0.001
Main model	2,506		0.93 (0.89-0.97)	<0.001		0.95 (0.92-1.00)	0.076
Stomach							
Simply adjusted model	3,024		0.92 (0.89-0.95)	<0.001		0.91 (0.87-0.94)	<0.001
Main model	2,375		0.96 (0.92-1.00)	0.054		0.94 (0.90-0.98)	0.019
Colon							
Simply adjusted model	4,586		0.91 (0.88-0.93)	<0.001		0.93 (0.90-0.96)	<0.001
Main model	3,634		0.94 (0.91-0.97)	<0.001		0.96 (0.92-0.99)	0.048
Rectum							
Simply adjusted model	3,624		0.92 (0.89-0.95)	<0.001		0.94 (0.91-0.98)	0.001
Main model	2,868		0.95 (0.91-0.99)	0.022		0.97 (0.93-1.01)	0.148
Hepatobiliary							
Simply adjusted model	3,175		0.89 (0.86-0.92)	<0.001		0.90 (0.86-0.93)	<0.001
Main model	2,482		0.93 (0.89-0.97)	0.005		0.93 (0.90-0.97)	0.010
Pancreas							
Simply adjusted model	3,286		0.90 (0.87-0.94)	<0.001		0.92 (0.89-0.96)	<0.001
Main model	2,576		0.95 (0.91-0.99)	0.022		0.96 (0.92-1.00)	0.076
Lung							
Simply adjusted model	4,741		0.86 (0.84-0.89)	<0.001		0.85 (0.82-0.88)	<0.001
Main model	3,642		0.93 (0.90-0.96)	<0.001		0.92 (0.89-0.96)	<0.001
Malignant melanoma							
Simply adjusted model	4,016		0.93 (0.90-0.96)	<0.001		0.99 (0.96-1.02)	0.389
Main model	3,172		0.95 (0.91-0.98)	0.022		1.00 (0.97-1.04)	0.933
Connective soft tissue							
Simply adjusted model	2,801		0.91 (0.88-0.95)	<0.001		0.92 (0.89-0.96)	<0.001
Main model	2,188		0.95 (0.90-0.99)	0.025		0.95 (0.91-1.00)	0.076
Breast							
Simply adjusted model	7,181		0.94 (0.91-0.96)	<0.001		0.95 (0.93-0.97)	<0.001
Main model	5,545		0.97 (0.94-1.00)	0.061		0.97 (0.95-1.00)	0.076
Uterus							
Simply adjusted model	3,445		0.89 (0.87-0.93)	<0.001		0.91 (0.88-0.94)	<0.001
Main model	2,672		0.96 (0.92-1.00)	0.060		0.96 (0.92-0.99)	0.076
Ovary							
Simply adjusted model	3,186		0.92 (0.89-0.95)	<0.001		0.93 (0.90-0.97)	<0.001
Main model	2,468		0.95 (0.91-0.99)	0.025		0.96 (0.92-1.00)	0.113
Prostate							
Simply adjusted model	8,271		1.00 (0.98-1.02)	0.802		1.02 (1.00-1.04)	0.061
Main model	6,778		1.01 (0.98-1.03)	0.558		1.03 (1.01-1.05)	0.049
Kidney							
Simply adjusted model	3,376		0.90 (0.87-0.93)	<0.001		0.93 (0.90-0.97)	<0.001
Main model	2,635		0.95 (0.91-0.99)	0.023		0.97 (0.93-1.01)	0.140
Bladder							
Simply adjusted model	3,263		0.91 (0.88-0.94)	<0.001		0.92 (0.89-0.95)	<0.001
Main model	2,572		0.95 (0.91-0.99)	0.025		0.96 (0.92-1.00)	0.076
Brain							
Simply adjusted model	3,075		0.92 (0.89-0.95)	<0.001		0.94 (0.91-0.98)	0.001
Main model	2,403		0.95 (0.91-0.99)	0.034		0.97 (0.93-1.02)	0.221
Thyroid							
Simply adjusted model	2,904		0.91 (0.88-0.95)	<0.001		0.93 (0.90-0.97)	<0.001
Main model	2,265		0.94 (0.90-0.99)	0.023		0.97 (0.92-1.01)	0.139
Lymphoma/Leukemia							
Simply adjusted model	4,928		0.94 (0.92-0.97)	<0.001		0.95 (0.92-0.98)	<0.001
Main model	3,840		0.98 (0.95-1.01)	0.205		0.97 (0.94-1.00)	0.111

0.85 0.9 0.95 1 1.05

0.85 0.9 0.95 1 1.05

Plasma omega-6 PUFAs

Plasma omega-3 PUFAs




Table 1. Baseline characteristics of included participants by quintiles of the plasma omega-6% (n = 253,138)

Characteristics ^a	Omega-6% quintiles					p-value
	1 (median = 32.9) (n = 50,628)	2 (median = 36.4) (n = 50,628)	3 (median = 38.4) (n = 50,628)	4 (median = 40.0) (n = 50,627)	5 (median = 42.1) (n = 50,627)	
Age (years)	57.6 (7.7)	57.7 (7.8)	57.1 (7.9)	55.9 (8.1)	53.6 (8.2)	<0.001 ^a
Gender (male%)	61.8	49.8	42.9	39.6	41.9	<0.001 ^b
Ethnicity (n%)						
White	46,982 (93.2%)	46,868 (92.9%)	46,597 (92.4%)	45,918 (91.1%)	43,857 (87.2%)	<0.001 ^b
Black	196 (0.4%)	229 (0.5%)	237 (0.5%)	256 (0.5%)	459 (0.9%)	
Asian	1,387 (2.8%)	1,514 (3.0%)	1,663 (3.3%)	1,948 (3.9%)	2,467 (4.9%)	
Others	1,831 (3.6%)	1,836 (3.6%)	1,933 (3.8%)	2,282 (4.5%)	3,530 (7.0%)	
Missing (n)	232	181	198	223	314	
TDI	-1.2 (3.2)	-1.4 (3.0)	-1.5 (3.0)	-1.5 (3.0)	-1.2 (3.2)	<0.001 ^a
Missing (n)	55	59	63	60	74	
BMI (kg/m ²)	29.8 (4.8)	28.4 (4.8)	27.3 (4.6)	26.4 (4.3)	25.4 (4.1)	<0.001 ^a
Missing (n)	225	192	172	153	207	
Smoking status (n%)						<0.001 ^b
Never	22,714 (45.1%)	26,033 (51.7%)	27,887 (55.3%)	29,650 (58.8%)	32,321 (64.2%)	
Previous	20,225 (40.2%)	18,554 (36.8%)	17,442 (34.6%)	16,228 (32.2%)	14,274 (28.3%)	
Current	7,392 (14.7%)	5,806 (11.5%)	5,080 (10.1%)	4,537 (9.0%)	3,778 (7.5%)	
Missing (n)	297	235	219	212	254	
Alcohol status (n%)						<0.001 ^b
Never	1,816 (3.6%)	1,893 (3.7%)	1,857 (3.7%)	2,169 (4.3%)	3,234 (6.4%)	
Previous	1,896 (3.8%)	1,665 (3.3%)	1,615 (3.2%)	1,636 (3.2%)	2,085 (4.1%)	
Current	46,786 (92.6%)	46,957 (93.0%)	47,063 (93.1%)	46,722 (92.5%)	45,139 (89.5%)	
Missing (n)	130	113	93	100	169	
Physical activity (n%)						<0.001 ^b
Low	9,713 (23.9%)	8,146 (20.1%)	7,398 (18.2%)	6,850 (16.7%)	6,576 (15.8%)	
Moderate	16,280 (40.1%)	16,700 (41.1%)	16,484 (40.5%)	16,564 (40.4%)	16,506 (39.7%)	
High	14,630 (36.0%)	15,739 (38.8%)	16,798 (41.3%)	17,614 (42.9%)	18,522 (44.5%)	
Missing (n)	10,005	10,043	9,948	9,599	9,023	

Abbreviations: omega-6%, omega-6 fatty acids to total fatty acids percentage; TDI, Townsend deprivation index; BMI, body mass index.

^a All variables measured at baseline are presented as mean (SD) unless otherwise specified.

^b From the ANOVA test for continuous variables.

^c From the Pearson's Chi-squared test for categorical variables.

Table 2. Associations of the plasma omega-6% with the incidence of overall cancer and 19 cancer sites in the UK Biobank

Cancer Type	Per 1-SD		Quintiles										P for overall ⁱ	Adjusted P for overall ^j	P for trend ^k	Adjusted P for trend ⁱ
	HR (95% CI)	Events	1	2	3	4	5									
	HR (95% CI)	Events	HR (95% CI)	Events	HR (95% CI)	Events	HR (95% CI)	Events								
Overall																
Simply adjusted model	0.94 (0.93-0.95)	6,787	1.00 (ref)	6,427	0.96 (0.93-0.99)	6,118	0.94 (0.90-0.97)	5,579	0.89 (0.86-0.92)	4,927	0.84 (0.81-0.88)	<0.001	--	<0.001	--	
Main model	0.98 (0.96-0.99)	5,356	1.00 (ref)	5,064	0.99 (0.95-1.03)	4,804	0.98 (0.94-1.02)	4,420	0.95 (0.91-0.99)	3,984	0.94 (0.90-0.98)	0.018	--	0.002	--	
Head and neck																
Simply adjusted model	0.94 (0.91-0.96)	1,344	1.00 (ref)	1,363	1.00 (0.93-1.08)	1,297	0.96 (0.89-1.04)	1,227	0.93 (0.86-1.00)	1,018	0.81 (0.75-0.88)	<0.001	<0.001	<0.001	<0.001	
Main model	0.97 (0.94-1.00)	1,062	1.00 (ref)	1,066	1.02 (0.94-1.11)	998	0.98 (0.89-1.07)	971	0.98 (0.89-1.07)	836	0.90 (0.81-0.99)	0.099	0.111	0.042	0.046	
Esophagus																
Simply adjusted model	0.89 (0.86-0.92)	784	1.00 (ref)	743	0.97 (0.87-1.07)	641	0.86 (0.78-0.96)	608	0.86 (0.77-0.96)	441	0.68 (0.61-0.77)	<0.001	<0.001	<0.001	<0.001	
Main model	0.93 (0.89-0.97)	619	1.00 (ref)	575	0.99 (0.88-1.11)	491	0.90 (0.80-1.02)	477	0.94 (0.83-1.06)	344	0.75 (0.66-0.87)	0.001	0.010	<0.001	0.003	
Additionally adjusted ^a	0.95 (0.91-0.99)	619	1.00 (ref)	575	1.01 (0.90-1.13)	491	0.93 (0.82-1.05)	477	0.98 (0.87-1.11)	344	0.79 (0.69-0.91)	0.006	--	0.009	--	
Stomach																
Simply adjusted model	0.92 (0.89-0.95)	703	1.00 (ref)	696	1.00 (0.90-1.11)	608	0.90 (0.81-1.01)	573	0.90 (0.80-1.00)	444	0.76 (0.67-0.86)	<0.001	<0.001	<0.001	<0.001	
Main model	0.96 (0.92-1.00)	556	1.00 (ref)	545	1.04 (0.92-1.17)	469	0.95 (0.83-1.07)	450	0.97 (0.85-1.10)	355	0.85 (0.73-0.98)	0.057	0.068	0.031	0.037	
Colon																
Simply adjusted model	0.91 (0.88-0.93)	1,107	1.00 (ref)	1,016	0.92 (0.85-1.01)	906	0.85 (0.78-0.93)	866	0.85 (0.78-0.93)	691	0.75 (0.68-0.83)	<0.001	<0.001	0.000	<0.001	
Main model	0.94 (0.91-0.97)	890	1.00 (ref)	798	0.94 (0.85-1.04)	709	0.88 (0.80-0.98)	688	0.92 (0.83-1.02)	549	0.81 (0.73-0.91)	0.006	0.023	0.001	0.003	
Additionally adjusted ^b	0.96 (0.92-0.99)	868	1.00 (ref)	773	0.95 (0.86-1.05)	692	0.91 (0.82-1.01)	670	0.95 (0.85-1.06)	540	0.86 (0.76-0.97)	0.105	--	0.018	--	
Rectum																
Simply adjusted model	0.92 (0.89-0.95)	864	1.00 (ref)	814	0.96 (0.88-1.06)	727	0.89 (0.81-0.98)	680	0.88 (0.79-0.97)	539	0.75 (0.68-0.84)	<0.001	<0.001	<0.001	<0.001	
Main model	0.95 (0.91-0.99)	684	1.00 (ref)	642	0.99 (0.89-1.11)	571	0.93 (0.83-1.04)	534	0.92 (0.82-1.04)	437	0.83 (0.73-0.94)	0.034	0.053	0.004	0.015	
Additionally adjusted ^b	0.96 (0.92-1.00)	667	1.00 (ref)	627	1.01 (0.90-1.13)	555	0.94 (0.84-1.06)	519	0.94 (0.84-1.06)	429	0.86 (0.75-0.98)	0.125	--	0.024	--	
Hepatobiliary																
Simply adjusted model	0.89 (0.86-0.92)	775	1.00 (ref)	738	0.96 (0.87-1.07)	637	0.86 (0.77-0.95)	575	0.82 (0.73-0.91)	450	0.70 (0.62-0.79)	<0.001	<0.001	<0.001	<0.001	
Main model	0.93 (0.89-0.97)	611	1.00 (ref)	580	1.01 (0.90-1.13)	489	0.91 (0.80-1.02)	445	0.89 (0.78-1.01)	357	0.79 (0.69-0.91)	0.003	0.019	<0.001	0.003	
Pancreas																
Simply adjusted model	0.90 (0.87-0.94)	777	1.00 (ref)	748	0.97 (0.87-1.07)	664	0.88 (0.79-0.98)	631	0.88 (0.79-0.98)	466	0.72 (0.64-0.81)	<0.001	<0.001	<0.001	<0.001	
Main model	0.95 (0.91-0.99)	613	1.00 (ref)	590	1.01 (0.90-1.13)	511	0.92 (0.82-1.04)	491	0.95 (0.84-1.08)	371	0.81 (0.70-0.93)	0.011	0.030	0.005	0.015	
Additionally adjusted ^c	0.95 (0.91-0.99)	613	1.00 (ref)	590	1.02 (0.91-1.14)	511	0.93 (0.82-1.05)	491	0.96 (0.85-1.09)	371	0.81 (0.71-0.93)	0.012	--	0.007	--	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.21.24301568>; this version posted January 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

Lung

Simply adjusted model	0.86 (0.84-0.89)	1,241	1.00 (ref)	1,066	0.86 (0.79-0.94)	945	0.79 (0.72-0.86)	856	0.75 (0.69-0.82)	633	0.62 (0.56-0.69)	<0.001	<0.001	<0.001	<0.001
Main model	0.93 (0.90-0.96)	947	1.00 (ref)	815	0.93 (0.84-1.02)	715	0.87 (0.79-0.96)	664	0.88 (0.79-0.97)	501	0.76 (0.68-0.85)	<0.001	<0.001	<0.001	<0.001
Additionally adjusted ^d	0.93 (0.90-0.96)	912	1.00 (ref)	788	0.93 (0.85-1.03)	691	0.87 (0.78-0.96)	647	0.88 (0.79-0.98)	486	0.76 (0.68-0.86)	<0.001	--	<0.001	--

Malignant melanoma

Simply adjusted model	0.93 (0.90-0.96)	874	1.00 (ref)	904	1.04 (0.94-1.14)	849	1.00 (0.90-1.09)	788	0.96 (0.87-1.06)	601	0.78 (0.71-0.87)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.91-0.98)	695	1.00 (ref)	710	1.05 (0.94-1.16)	663	1.01 (0.91-1.13)	615	0.98 (0.88-1.10)	489	0.85 (0.75-0.96)	0.008	0.025	0.021	0.033
Additionally adjusted ^e	0.95 (0.92-0.99)	695	1.00 (ref)	710	1.05 (0.94-1.17)	663	1.02 (0.92-1.14)	615	0.98 (0.88-1.10)	489	0.86 (0.76-0.98)	0.014	--	0.043	--

Connective soft tissue

Simply adjusted model	0.91 (0.88-0.95)	645	1.00 (ref)	644	1.00 (0.90-1.12)	569	0.91 (0.81-1.02)	539	0.90 (0.80-1.01)	404	0.74 (0.65-0.84)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.90-0.99)	512	1.00 (ref)	498	1.02 (0.90-1.15)	438	0.94 (0.82-1.07)	419	0.95 (0.83-1.09)	321	0.81 (0.70-0.94)	0.022	0.044	0.010	0.022

Breast

Simply adjusted model	0.94 (0.91-0.96)	1,323	1.00 (ref)	1,516	0.98 (0.91-1.06)	1,555	0.94 (0.87-1.01)	1,485	0.89 (0.82-0.96)	1,302	0.84 (0.77-0.91)	<0.001	<0.001	<0.001	<0.001
Main model	0.97 (0.94-1.00)	1,025	1.00 (ref)	1,153	0.99 (0.91-1.07)	1,176	0.95 (0.88-1.04)	1,149	0.93 (0.85-1.02)	1,042	0.92 (0.83-1.01)	0.292	0.308	0.032	0.037
Additionally adjusted ^f	1.01 (0.97-1.05)	523	1.00 (ref)	726	1.01 (0.91-1.14)	836	1.02 (0.91-1.14)	855	1.00 (0.89-1.12)	807	1.01 (0.90-1.14)	0.991	--	0.927	--

Uterus

Simply adjusted model	0.89 (0.87-0.93)	772	1.00 (ref)	788	0.97 (0.88-1.08)	722	0.89 (0.80-0.98)	673	0.86 (0.77-0.95)	490	0.69 (0.61-0.77)	<0.001	<0.001	<0.001	<0.001
Main model	0.96 (0.92-1.00)	602	1.00 (ref)	602	1.02 (0.91-1.14)	557	0.98 (0.87-1.10)	526	0.99 (0.88-1.12)	385	0.82 (0.72-0.94)	0.018	0.043	0.026	0.037
Additionally adjusted ^g	0.97 (0.91-1.04)	220	1.00 (ref)	286	1.00 (0.84-1.19)	328	1.07 (0.90-1.26)	314	1.00 (0.88-1.25)	209	0.81 (0.66-0.99)	0.022	--	0.971	--

Ovary

Simply adjusted model	0.92 (0.89-0.95)	697	1.00 (ref)	731	1.02 (0.92-1.13)	647	0.90 (0.81-1.01)	630	0.91 (0.82-1.02)	481	0.77 (0.68-0.86)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.91-0.99)	552	1.00 (ref)	558	1.02 (0.90-1.15)	492	0.92 (0.81-1.04)	489	0.96 (0.85-1.09)	377	0.82 (0.72-0.95)	0.023	0.044	0.011	0.022
Additionally adjusted ^g	0.99 (0.92-1.06)	164	1.00 (ref)	239	1.06 (0.87-1.29)	263	1.06 (0.87-1.29)	274	1.11 (0.91-1.35)	196	0.89 (0.71-1.11)	0.151	--	0.554	--

Prostate

Simply adjusted model	1.00 (0.98-1.02)	1,962	1.00 (ref)	1,853	1.08 (1.01-1.15)	1,640	1.08 (1.01-1.15)	1,532	1.09 (1.02-1.16)	1,284	0.96 (0.90-1.03)	0.001	0.001	0.902	0.902
Main model	1.01 (0.98-1.03)	1,600	1.00 (ref)	1,524	1.09 (1.02-1.17)	1,347	1.08 (1.01-1.17)	1,253	1.09 (1.01-1.17)	1,054	0.97 (0.90-1.06)	0.005	0.023	0.765	0.765
Additionally adjusted ^h	1.01 (0.98-1.03)	1,555	1.00 (ref)	1,488	1.10 (1.02-1.18)	1,321	1.09 (1.01-1.17)	1,219	1.09 (1.00-1.17)	1,034	0.98 (0.90-1.06)	0.005	--	0.719	--

Kidney

Simply adjusted model	0.90 (0.87-0.93)	813	1.00 (ref)	758	0.95 (0.86-1.05)	686	0.89 (0.80-0.98)	636	0.86 (0.78-0.96)	483	0.71 (0.64-0.80)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.91-0.99)	638	1.00 (ref)	591	0.99 (0.88-1.11)	523	0.93 (0.83-1.05)	495	0.95 (0.84-1.07)	388	0.83 (0.72-0.95)	0.051	0.065	0.011	0.022

Bladder

Simply adjusted model	0.91 (0.88-0.94)	781	1.00 (ref)	746	0.98 (0.88-1.08)	652	0.89 (0.80-0.99)	623	0.90 (0.81-1.00)	461	0.73 (0.65-0.82)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.91-0.99)	613	1.00 (ref)	586	1.02 (0.91-1.15)	512	0.95 (0.85-1.08)	489	0.98 (0.87-1.11)	372	0.84 (0.73-0.96)	0.040	0.054	0.028	0.037

Brain

Simply adjusted model	0.92 (0.89-0.95)	704	1.00 (ref)	705	1.01 (0.91-1.12)	621	0.92 (0.82-1.02)	594	0.92 (0.82-1.02)	451	0.76 (0.67-0.86)	<0.001	<0.001	<0.001	<0.001
Main model	0.95 (0.91-0.99)	555	1.00 (ref)	547	1.03 (0.91-1.16)	481	0.95 (0.84-1.08)	458	0.96 (0.84-1.09)	362	0.83 (0.72-0.96)	0.036	0.053	0.017	0.029

Thyroid

Simply adjusted model	0.91 (0.88-0.95)	668	1.00 (ref)	653	0.97 (0.87-1.09)	591	0.90 (0.80-1.01)	561	0.89 (0.79-0.99)	431	0.74 (0.65-0.84)	<0.001	<0.001	<0.001	<0.001
Main model	0.94 (0.90-0.99)	529	1.00 (ref)	506	0.99 (0.88-1.12)	457	0.93 (0.82-1.06)	434	0.93 (0.82-1.07)	339	0.80 (0.69-0.93)	0.026	0.045	0.006	0.015

Lymphoid and Hematopoietic Tissues

Simply adjusted model	0.94 (0.88-0.97)	1,113	1.00 (ref)	1,105	1.01 (0.93-1.09)	1,007	0.95 (0.87-1.03)	916	0.91 (0.83-0.99)	787	0.86 (0.78-0.94)	0.003	0.003	<0.001	<0.001
Main model	0.98 (0.95-1.01)	873	1.00 (ref)	854	1.03 (0.93-1.13)	783	0.99 (0.90-1.10)	717	0.97 (0.88-1.08)	613	0.93 (0.83-1.03)	0.446	0.446	0.174	0.183

Abbreviations: omega-6%, omega-6 fatty acids to total fatty acids percentage; SD, standard deviation; CI, confidence interval; HR, hazards ratio; ref, reference.

The results from simply adjusted models revealed the associations of plasma omega-6% with cancer risk stratified by age and sex in general cohort. The main models were adjusted for general covariates including ethnicity (classified into White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Center, BMI (kg/m²; continuous), smoking status (categorized as never, previous, current), alcohol intake status (categorized as never, previous, current), and physical activity (classified as low, moderate, high). The additionally adjusted models were adjusted for extra covariates for some specific types of cancer.

^a Additionally adjusted for gastroesophageal reflux disease at baseline and waist-hip ratio.

^b Additionally adjusted for diabetes at baseline, aspirin use, processed meat intake, waist-hip ratio, and family history.

^c Additionally adjusted for diabetes at baseline.

^d Additionally adjusted for family history.

^e Additionally adjusted for skin color, ease of skin tanning, use of sun/UV protection, childhood sunburn occasions, frequency of solarium/sunlamp use.

^f Restricted to female, and additionally adjusted for age when menarche started, hormone replacement therapy use, oral contraceptive use, number of live births, menopausal status, hysterectomy status, and family history.

^g Restricted to female, and additionally adjusted for age when menarche started, hormone replacement therapy use, oral contraceptive use, number of live births, menopausal status, hysterectomy status.

^h Restricted to male, and additionally adjusted for family history.

ⁱ Used likelihood ratio test to compare the full model with reduced model.

^j Based on False Discovery Rate (FDR) to calculate the adjusted p-values for simply adjusted models and main models among 19 cancer sites.

^k Used the median value of each quintile as a continuous variable within the models.

Table 3. Associations of the plasma omega-3% with the incidence of overall cancer and 19 cancer sites in the UK Biobank

Cancer Type	Per 1-SD		Quintiles									P for overall ⁱ	Adjusted P for overall ^j	P for trend ^k	Adjusted P for trend ^l	
	HR (95% CI)	Events	1	2	3	4	5									
	HR (95% CI)	Events	HR (95% CI)	Events	HR (95% CI)	Events	HR (95% CI)									
Overall																
Simply adjusted model	0.96 (0.95-0.97)	5,864	1.00 (ref)	5,837	0.95 (0.92-0.99)	5,935	0.92 (0.89-0.96)	6,086	0.91 (0.88-0.95)	6,116	0.88 (0.85-0.91)	<0.001	--	<0.001	--	
Main model	0.99 (0.97-1.00)	4,546	1.00 (ref)	4,603	0.97 (0.93-1.01)	4,688	0.95 (0.91-0.99)	4,838	0.95 (0.91-0.99)	4,953	0.95 (0.91-0.99)	0.080	--	0.022	--	
Head and neck																
Simply adjusted model	0.95 (0.93-0.98)	1,267	1.00 (ref)	1,185	0.89 (0.83-0.97)	1,252	0.90 (0.84-0.98)	1,275	0.89 (0.82-0.96)	1,270	0.84 (0.78-0.91)	0.001	0.001	<0.001	<0.001	
Main model	0.97 (0.95-1.00)	985	1.00 (ref)	928	0.91 (0.83-1.00)	1,004	0.95 (0.87-1.04)	988	0.91 (0.83-1.00)	1,028	0.92 (0.84-1.01)	0.205	0.493	0.150	0.192	
Esophagus																
Simply adjusted model	0.92 (0.88-0.95)	685	1.00 (ref)	600	0.83 (0.75-0.93)	664	0.87 (0.78-0.97)	626	0.79 (0.71-0.88)	642	0.77 (0.69-0.86)	<0.001	<0.001	<0.001	<0.001	
Main model	0.95 (0.92-1.00)	510	1.00 (ref)	468	0.88 (0.78-1.00)	523	0.95 (0.84-1.07)	494	0.87 (0.77-0.99)	511	0.88 (0.78-1.00)	0.163	0.493	0.089	0.188	
Additionally adjusted ^a	0.96 (0.92-1.00)	510	1.00 (ref)	468	0.88 (0.78-1.00)	523	0.95 (0.84-1.08)	494	0.88 (0.77-0.99)	511	0.89 (0.79-1.02)	0.187	--	0.128	--	
Stomach																
Simply adjusted model	0.91 (0.87-0.94)	648	1.00 (ref)	561	0.82 (0.73-0.92)	622	0.86 (0.77-0.96)	603	0.80 (0.71-0.89)	590	0.74 (0.66-0.83)	<0.001	<0.001	<0.001	<0.001	
Main model	0.94 (0.90-0.98)	494	1.00 (ref)	442	0.86 (0.76-0.98)	491	0.92 (0.81-1.04)	476	0.86 (0.76-0.98)	472	0.83 (0.73-0.95)	0.051	0.242	0.015	0.076	
Colon																
Simply adjusted model	0.93 (0.90-0.96)	952	1.00 (ref)	848	0.84 (0.77-0.92)	938	0.88 (0.80-0.96)	906	0.81 (0.74-0.89)	942	0.79 (0.72-0.87)	<0.001	<0.001	<0.001	<0.001	
Main model	0.96 (0.92-0.99)	727	1.00 (ref)	675	0.88 (0.79-0.98)	759	0.94 (0.85-1.04)	718	0.86 (0.77-0.95)	755	0.87 (0.78-0.97)	0.021	0.152	0.016	0.076	
Additionally adjusted ^b	0.95 (0.92-0.99)	710	1.00 (ref)	659	0.86 (0.78-0.96)	735	0.91 (0.82-1.01)	703	0.84 (0.75-0.93)	736	0.85 (0.76-0.95)	0.009	--	0.006	--	
Rectum																
Simply adjusted model	0.94 (0.91-0.98)	726	1.00 (ref)	676	0.89 (0.80-0.99)	751	0.94 (0.85-1.04)	744	0.90 (0.81-1.00)	727	0.84 (0.76-0.93)	0.017	0.019	0.003	0.004	
Main model	0.97 (0.93-1.01)	552	1.00 (ref)	536	0.93 (0.83-1.05)	605	1.01 (0.90-1.14)	591	0.97 (0.86-1.09)	584	0.93 (0.82-1.05)	0.494	0.575	0.343	0.383	
Additionally adjusted ^b	0.97 (0.93-1.00)	538	1.00 (ref)	524	0.92 (0.82-1.04)	584	0.98 (0.87-1.10)	580	0.95 (0.84-1.07)	571	0.91 (0.80-1.03)	0.475	--	0.198	--	
Hepatobiliary																
Simply adjusted model	0.90 (0.86-0.93)	695	1.00 (ref)	593	0.81 (0.72-0.90)	647	0.83 (0.75-0.93)	619	0.76 (0.68-0.85)	621	0.72 (0.65-0.81)	<0.001	<0.001	<0.001	<0.001	
Main model	0.93 (0.90-0.97)	519	1.00 (ref)	470	0.87 (0.77-0.98)	513	0.91 (0.80-1.03)	488	0.84 (0.74-0.95)	492	0.82 (0.72-0.94)	0.024	0.152	0.005	0.047	
Pancreas																
Simply adjusted model	0.92 (0.89-0.96)	671	1.00 (ref)	611	0.86 (0.77-0.96)	665	0.88 (0.79-0.97)	672	0.84 (0.75-0.94)	667	0.78 (0.70-0.87)	<0.001	<0.001	<0.001	<0.001	
Main model	0.96 (0.92-1.00)	507	1.00 (ref)	475	0.89 (0.79-1.01)	528	0.95 (0.84-1.07)	531	0.92 (0.81-1.04)	535	0.89 (0.79-1.01)	0.351	0.493	0.152	0.192	
Additionally adjusted ^c	0.96 (0.92-1.00)	507	1.00 (ref)	475	0.89 (0.79-1.01)	528	0.94 (0.83-1.07)	531	0.90 (0.81-1.03)	535	0.89 (0.78-1.00)	0.312	--	0.126	--	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.21.24301568>; this version posted January 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

Lung															
Simply adjusted model	0.85 (0.82-0.88)	1,067	1.00 (ref)	941	0.82 (0.76-0.90)	959	0.78 (0.72-0.86)	904	0.70 (0.64-0.76)	870	0.63 (0.57-0.69)	<0.001	<0.001	<0.001	<0.001
Main model	0.92 (0.89-0.96)	789	1.00 (ref)	720	0.90 (0.82-1.00)	744	0.92 (0.83-1.01)	698	0.84 (0.76-0.93)	691	0.81 (0.73-0.91)	0.001	0.019	<0.001	0.002
Additionally adjusted ^d	0.92 (0.89-0.96)	759	1.00 (ref)	695	0.90 (0.81-1.00)	721	0.91 (0.82-1.01)	676	0.83 (0.75-0.93)	673	0.81 (0.73-0.91)	0.001	--	<0.001	--
Malignant melanoma															
Simply adjusted model	0.99 (0.96-1.02)	768	1.00 (ref)	735	0.91 (0.83-1.01)	810	0.96 (0.87-1.06)	846	0.97 (0.88-1.07)	857	0.94 (0.85-1.03)	0.477	0.477	0.467	0.467
Main model	1.00 (0.97-1.04)	590	1.00 (ref)	583	0.94 (0.84-1.06)	650	1.00 (0.90-1.12)	677	1.01 (0.90-1.13)	672	0.97 (0.87-1.09)	0.699	0.699	0.998	0.998
Additionally adjusted ^e	1.01 (0.97-1.04)	590	1.00 (ref)	583	0.94 (0.84-1.06)	650	1.01 (0.90-1.13)	677	1.02 (0.91-1.14)	672	0.99 (0.88-1.11)	0.686	--	0.758	--
Connective soft tissue															
Simply adjusted model	0.92 (0.89-0.96)	581	1.00 (ref)	517	0.84 (0.75-0.95)	577	0.89 (0.79-1.00)	565	0.83 (0.74-0.94)	561	0.78 (0.70-0.88)	0.001	0.001	<0.001	<0.001
Main model	0.95 (0.91-1.00)	436	1.00 (ref)	407	0.90 (0.78-1.03)	456	0.96 (0.84-1.10)	445	0.91 (0.80-1.04)	444	0.88 (0.77-1.01)	0.323	0.493	0.118	0.192
Breast															
Simply adjusted model	0.95 (0.93-0.97)	1,295	1.00 (ref)	1,341	0.95 (0.88-1.02)	1,405	0.92 (0.85-0.99)	1,540	0.92 (0.85-0.99)	1,600	0.87 (0.80-0.93)	0.004	0.005	<0.001	<0.001
Main model	0.97 (0.95-1.00)	965	1.00 (ref)	1,048	0.99 (0.91-1.08)	1,076	0.95 (0.87-1.04)	1,194	0.96 (0.88-1.05)	1,262	0.94 (0.86-1.02)	0.545	0.575	0.118	0.192
Additionally adjusted ^f	0.98 (0.95-1.01)	620	1.00 (ref)	705	1.00 (0.90-1.12)	677	0.89 (0.80-0.99)	845	0.98 (0.88-1.09)	900	0.93 (0.84-1.03)	0.108	--	0.194	--
Uterus															
Simply adjusted model	0.91 (0.88-0.94)	678	1.00 (ref)	647	0.89 (0.79-0.99)	714	0.91 (0.82-1.01)	710	0.84 (0.76-0.94)	696	0.76 (0.68-0.85)	<0.001	<0.001	<0.001	<0.001
Main model	0.96 (0.92-0.99)	507	1.00 (ref)	501	0.92 (0.82-1.05)	552	0.96 (0.85-1.09)	556	0.92 (0.82-1.04)	556	0.89 (0.78-1.00)	0.376	0.493	0.079	0.188
Additionally adjusted ^g	1.00 (0.95-1.05)	210	1.00 (ref)	234	0.97 (0.81-1.16)	259	0.96 (0.80-1.15)	323	1.05 (0.88-1.25)	331	0.97 (0.82-1.16)	0.817	--	0.971	--
Ovary															
Simply adjusted model	0.93 (0.90-0.97)	646	1.00 (ref)	576	0.83 (0.74-0.93)	631	0.85 (0.76-0.95)	664	0.84 (0.75-0.94)	669	0.79 (0.71-0.88)	0.001	0.001	<0.001	<0.001
Main model	0.96 (0.92-1.00)	485	1.00 (ref)	452	0.88 (0.78-1.00)	487	0.90 (0.80-1.02)	519	0.91 (0.81-1.04)	525	0.88 (0.77-1.00)	0.287	0.493	0.147	0.192
Additionally adjusted ^g	1.01 (0.95-1.07)	187	1.00 (ref)	184	0.86 (0.70-1.05)	193	0.80 (0.66-0.98)	276	0.99 (0.82-1.19)	296	0.92 (0.76-1.11)	0.105	--	0.888	--
Prostate															
Simply adjusted model	1.02 (1.00-1.04)	1,605	1.00 (ref)	1,637	1.01 (0.94-1.08)	1,723	1.04 (0.97-1.12)	1,635	1.02 (0.95-1.09)	1,671	1.07 (1.00-1.14)	0.337	0.356	0.065	0.069
Main model	1.03 (1.01-1.05)	1,276	1.00 (ref)	1,332	1.02 (0.94-1.10)	1,419	1.06 (0.98-1.14)	1,360	1.04 (0.96-1.12)	1,391	1.08 (1.00-1.17)	0.275	0.493	0.041	0.154
Additionally adjusted ^h	1.03 (1.00-1.05)	1,239	1.00 (ref)	1,302	1.02 (0.95-1.10)	1,389	1.06 (0.98-1.15)	1,331	1.04 (0.96-1.12)	1,356	1.08 (1.00-1.17)	0.346	--	0.060	--
Kidney															
Simply adjusted model	0.93 (0.90-0.97)	701	1.00 (ref)	647	0.88 (0.79-0.98)	680	0.88 (0.79-0.97)	677	0.84 (0.75-0.93)	671	0.79 (0.71-0.88)	0.001	0.001	<0.001	<0.001
Main model	0.97 (0.93-1.01)	527	1.00 (ref)	512	0.93 (0.83-1.06)	525	0.92 (0.82-1.04)	532	0.91 (0.81-1.03)	539	0.90 (0.80-1.02)	0.526	0.575	0.133	0.192
Bladder															
Simply adjusted model	0.92 (0.89-0.95)	680	1.00 (ref)	614	0.86 (0.77-0.95)	663	0.87 (0.78-0.97)	661	0.83 (0.75-0.93)	645	0.77 (0.69-0.86)	<0.001	<0.001	<0.001	<0.001
Main model	0.96 (0.92-1.00)	518	1.00 (ref)	482	0.89 (0.79-1.01)	526	0.93 (0.83-1.06)	526	0.91 (0.80-1.03)	520	0.88 (0.77-0.99)	0.269	0.493	0.080	0.188

	HR	N	Ref	N	HR	N	HR	N	HR	N	HR	N	HR	N	HR	N
Brain																
Simply adjusted model	0.94 (0.91-0.98)	634	1.00 (ref)	560	0.84 (0.75-0.94)	634	0.90 (0.81-1.01)	621	0.85 (0.76-0.95)	626	0.81 (0.72-0.91)	0.003	0.004	0.001	0.002	
Main model	0.97 (0.93-1.02)	473	1.00 (ref)	434	0.88 (0.77-1.01)	506	0.99 (0.87-1.12)	488	0.92 (0.81-1.05)	502	0.92 (0.81-1.05)	0.286	0.493	0.407	0.430	
Thyroid																
Simply adjusted model	0.93 (0.90-0.97)	593	1.00 (ref)	534	0.85 (0.76-0.96)	599	0.91 (0.81-1.01)	585	0.84 (0.75-0.95)	593	0.81 (0.72-0.91)	0.005	0.006	0.001	0.002	
Main model	0.97 (0.92-1.01)	445	1.00 (ref)	415	0.89 (0.78-1.02)	473	0.98 (0.86-1.11)	461	0.92 (0.80-1.05)	471	0.91 (0.79-1.04)	0.389	0.493	0.268	0.318	
Lymphoid and Hematopoietic Tissues																
Simply adjusted model	0.95 (0.92-0.98)	980	1.00 (ref)	942	0.91 (0.83-1.00)	1,009	0.92 (0.84-1.01)	989	0.86 (0.79-0.94)	1,008	0.83 (0.76-0.91)	0.001	0.001	<0.001	<0.001	
Main model	0.97 (0.94-1.00)	747	1.00 (ref)	725	0.92 (0.83-1.02)	789	0.95 (0.86-1.06)	782	0.91 (0.82-1.01)	797	0.9 (0.81-0.99)	0.249	0.493	0.055	0.175	

Abbreviations: omega-3%, omega-3 fatty acids to total fatty acids percentage; SD, standard deviation; CI, confidence interval; HR, hazards ratio; ref, reference.

The results from simply adjusted models revealed the associations of plasma omega-3% with cancer risk stratified by age and sex in general cohort. The main models were adjusted for general covariates including ethnicity (classified into White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Center, BMI (kg/m²; continuous), smoking status (categorized as never, previous, current), alcohol intake status (categorized as never, previous, current), and physical activity (classified as low, moderate, high). The additionally adjusted models were adjusted for extra covariates for some specific types of cancer.

^a Additionally adjusted for gastroesophageal reflux disease at baseline and waist-hip ratio.

^b Additionally adjusted for diabetes at baseline, aspirin use, processed meat intake, waist-hip ratio, and family history.

^c Additionally adjusted for diabetes at baseline.

^d Additionally adjusted for family history.

^e Additionally adjusted for skin color, ease of skin tanning, use of sun/UV protection, childhood sunburn occasions, frequency of solarium/sunlamp use.

^f Restricted to female, and additionally adjusted for age when menarche started, hormone replacement therapy use, oral contraceptive use, number of live births, menopausal status, hysterectomy status, and family history.

^g Restricted to female, and additionally adjusted for age when menarche started, hormone replacement therapy use, oral contraceptive use, number of live births, menopausal status, hysterectomy status.

^h Restricted to male, and additionally adjusted for family history.

ⁱ Used likelihood ratio test to compare the full model with reduced model.

^j Based on False Discovery Rate (FDR) to calculate the adjusted p-values for simply adjusted models and main models among 19 cancer sites.

^k Used the median value of each quintile as a continuous variable within the models.

Table 4. Risk estimates^a of plasma omega-6% and omega-3% with incidence of overall cancer, stratified by potential risk factors, in the UK Biobank Study (n = 253,138)

Stratified variables			Overall Cancer												
			Continuous P for interaction	Events & HR (95% CI) across quintiles										P for trend	Categorical P for interaction
			1	2	3	4	5								
Age, years	ω-6	< 58	< 0.001	1,873	1.00 (ref)	1,718	0.94 (0.88-1.01)	1,872	0.95 (0.88-1.02)	2,026	0.90 (0.83-0.97)	2,343	0.89 (0.83-0.96)	0.001	0.093
		≥ 58		4,914	1.00 (ref)	4,709	1.01 (0.96-1.06)	4,246	0.99 (0.95-1.04)	3,553	0.97 (0.92-1.02)	2,584	0.92 (0.87-0.97)	0.006	
	ω-3	< 58	< 0.001	2,474	1.00 (ref)	2,243	1.01 (0.94-1.07)	1,944	0.97 (0.91-1.04)	1,732	1.01 (0.94-1.08)	1,439	1.03 (0.96-1.11)	0.421	< 0.001
		≥ 58		3,390	1.00 (ref)	3,594	0.95 (0.90-1.00)	3,991	0.95 (0.90-1.00)	4,354	0.95 (0.90-1.00)	4,677	0.95 (0.90-1.00)	0.106	
Sex	ω-6	Male	--	4,299	1.00 (ref)	3,463	1.01 (0.96-1.06)	2,930	1.01 (0.95-1.06)	2,531	0.97 (0.91-1.02)	2,304	0.94 (0.89-1.00)	0.048	0.006
		Female		2,488	1.00 (ref)	2,964	0.95 (0.89-1.01)	3,188	0.94 (0.89-1.00)	3,048	0.92 (0.87-0.98)	2,623	0.91 (0.85-0.98)	0.006	
	ω-3	Male	--	3,554	1.00 (ref)	3,260	0.95 (0.90-1.00)	3,175	0.95 (0.90-1.00)	2,885	0.93 (0.88-0.98)	2,653	0.94 (0.89-0.99)	0.03	0.002
		Female		2,310	1.00 (ref)	2,577	1.00 (0.94-1.07)	2,760	0.96 (0.90-1.03)	3,201	0.99 (0.93-1.05)	3,463	0.97 (0.91-1.03)	0.337	
TDI	ω-6	< -2	0.346	3,381	1.00 (ref)	3,461	1.01 (0.95-1.06)	3,333	1.00 (0.95-1.06)	3,026	0.96 (0.91-1.02)	2,587	0.96 (0.90-1.02)	0.101	0.732
		≥ -2		3,400	1.00 (ref)	2,962	0.97 (0.92-1.03)	2,780	0.96 (0.91-1.02)	2,548	0.94 (0.89-1.00)	2,333	0.91 (0.86-0.97)	0.005	
	ω-3	< -2	0.030	2,606	1.00 (ref)	2,934	0.98 (0.93-1.04)	3,185	0.96 (0.91-1.02)	3,466	1.01 (0.95-1.07)	3,597	0.99 (0.93-1.05)	0.942	0.094
		≥ -2		3,251	1.00 (ref)	2,894	0.95 (0.90-1.01)	2,750	0.94 (0.88-0.99)	2,613	0.89 (0.84-0.94)	2,515	0.91 (0.86-0.97)	< 0.001	
BMI, kg/m ²	ω-6	< 25	0.228	838	1.00 (ref)	1,381	0.95 (0.87-1.05)	1,876	0.96 (0.88-1.06)	2,190	0.93 (0.85-1.02)	2,357	0.88 (0.81-0.96)	0.003	0.446
		≥ 25		5,924	1.00 (ref)	5,019	0.98 (0.94-1.03)	4,213	0.97 (0.92-1.01)	3,371	0.93 (0.88-0.97)	2,558	0.94 (0.89-0.99)	0.001	
	ω-3	< 25	0.756	1,740	1.00 (ref)	1,517	0.95 (0.88-1.03)	1,588	0.95 (0.88-1.02)	1,710	0.93 (0.86-1.01)	2,087	0.91 (0.85-0.98)	0.018	0.439
		≥ 25		4,107	1.00 (ref)	4,301	0.98 (0.93-1.02)	4,316	0.95 (0.90-1.00)	4,355	0.96 (0.91-1.00)	4,006	0.96 (0.91-1.01)	0.105	
Current smoking status	ω-6	Yes	--	1,166	1.00 (ref)	863	0.95 (0.86-1.05)	764	0.96 (0.86-1.07)	574	0.85 (0.76-0.96)	471	0.95 (0.83-1.07)	0.07	0.380
		No		5,574	1.00 (ref)	5,535	0.99 (0.95-1.03)	5,327	0.98 (0.94-1.02)	4,969	0.96 (0.92-1.00)	4,430	0.93 (0.88-0.97)	0.001	

Current alcohol status	ω -3	Yes	--	1,311	1.00 (ref)	902	0.90 (0.81-0.99)	708	0.84 (0.76-0.94)	536	0.84 (0.75-0.95)	381	0.78 (0.69-0.89)	< 0.001	0.017	
		No		4,520	1.00 (ref)	4,902	0.99 (0.95-1.04)	5,191	0.98 (0.93-1.02)	5,518	0.98 (0.94-1.03)	5,704	0.98 (0.94-1.03)	0.48		
	ω -6	Yes	--	6,243	1.00 (ref)	5,957	1.00 (0.96-1.04)	5,676	0.99 (0.95-1.03)	5,147	0.96 (0.92-1.00)	4,398	0.94 (0.90-0.99)	0.007		0.408
		No		529	1.00 (ref)	459	0.90 (0.77-1.04)	429	0.92 (0.79-1.07)	418	0.87 (0.74-1.02)	515	0.86 (0.74-1.01)	0.055		
Physical activity	ω -3	Yes	--	5,210	1.00 (ref)	5,364	0.97 (0.93-1.01)	5,499	0.95 (0.91-0.99)	5,652	0.95 (0.91-0.99)	5,696	0.95 (0.91-0.99)	0.019	0.974	
		No		638	1.00 (ref)	462	0.97 (0.84-1.11)	417	0.95 (0.82-1.10)	426	0.95 (0.82-1.10)	407	1.00 (0.86-1.16)	0.93		
	ω -6	Low or moderate	--	3,551	1.00 (ref)	3,204	0.99 (0.95-1.04)	2,888	0.98 (0.93-1.03)	2,589	0.95 (0.90-1.00)	2,290	0.93 (0.88-0.99)	0.007		0.974
		High		1,875	1.00 (ref)	1,909	0.98 (0.92-1.05)	1,972	0.99 (0.93-1.06)	1,882	0.96 (0.90-1.03)	1,741	0.94 (0.88-1.01)	0.089		
ω -3	Low or moderate	--	2,750	1.00 (ref)	2,876	0.99 (0.94-1.04)	2,893	0.96 (0.91-1.01)	3,026	0.96 (0.91-1.01)	2,977	0.96 (0.91-1.01)	0.099	0.844		
	High		1,848	1.00 (ref)	1,780	0.94 (0.88-1.00)	1,848	0.94 (0.88-1.00)	1,870	0.94 (0.88-1.00)	2,033	0.93 (0.87-1.00)	0.089			

Abbreviations: omega-6%, omega-6 fatty acids to total fatty acids percentage; omega-3%, omega-3 fatty acids to total fatty acids percentage; CI, confidence interval; HR, hazards ratio; ref, reference.

^a From Cox proportional hazards regression; results were based on the main models, stratified by age and sex, and adjusted for ethnicity (classified into White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Center, BMI (kg/m²; continuous), smoking status (categorized as never, previous, current), alcohol intake status (categorized as never, previous, current), and physical activity (classified as low, moderate, high).